These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2513995)

  • 1. Biochemistry and pharmacology of cyclooxygenase inhibitors.
    Bailey JM
    Bull N Y Acad Med; 1989 Jan; 65(1):5-15. PubMed ID: 2513995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems.
    Sharma S; Sharma SC
    Indian J Exp Biol; 1997 Oct; 35(10):1025-31. PubMed ID: 9475035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
    Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
    Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
    Frommel TO; Dyavanapalli M; Oldham T; Kazi N; Lietz H; Liao Y; Mobarhan S
    Clin Cancer Res; 1997 Feb; 3(2):209-13. PubMed ID: 9815674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory activity of a dual inhibitor of cyclooxygenase and lipoxygenase pathways, CBS-1108 (2-acetylthiophene-2-thiazolylhydrazone).
    Sincholle D; Bertez C; Legrand A; Conduzorgues JP; Bonne C
    Arzneimittelforschung; 1985; 35(8):1260-3. PubMed ID: 3935121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
    Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
    Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Essential unsaturated fatty acids].
    Yamamoto S
    Nihon Rinsho; 1999 Oct; 57(10):2242-6. PubMed ID: 10540869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
    Gaddi A; Cicero AF; Pedro EJ
    Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eicosanoids, inflammation, and anti-inflammatory drugs.
    Robinson DR
    Clin Exp Rheumatol; 1989; 7 Suppl 3():S155-61. PubMed ID: 2691152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The broken balance in aspirin hypersensitivity.
    Szczeklik A; Sanak M
    Eur J Pharmacol; 2006 Mar; 533(1-3):145-55. PubMed ID: 16457808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts.
    Kähler CM; Herold M; Reinisch N; Wiedermann CJ
    J Cell Physiol; 1996 Mar; 166(3):601-8. PubMed ID: 8600164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses.
    Botting RM
    J Physiol Pharmacol; 2006 Nov; 57 Suppl 5():113-24. PubMed ID: 17218763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibitors and metabolism of essential fatty acids.
    Das UN
    Med Sci Monit; 2005 Jul; 11(7):RA233-7. PubMed ID: 15990700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of the leukotrienes].
    Sirois P; Borgeat P
    J Pharmacol; 1984; 15 Suppl 1():53-68. PubMed ID: 6328128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid.
    Bhattacharyya DK; Lecomte M; Dunn J; Morgans DJ; Smith WL
    Arch Biochem Biophys; 1995 Feb; 317(1):19-24. PubMed ID: 7872783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of anti-inflammatory treatment--new ways of thinking.
    Brune K
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cytokine production by eicosanoids and nitric oxide.
    Marcinkiewicz J
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):163-7. PubMed ID: 9597082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eicosanoids in rheumatoid arthritis.
    Sperling RI
    Rheum Dis Clin North Am; 1995 Aug; 21(3):741-58. PubMed ID: 8619097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.